PHARMAECONOMIC ASPECTS OF TREATING ALZHEIMER’S DISEASE
Abstract
The authors have conducted pharmacoeconomic analysis of the use of Cerebrolysin, galantamine, rivastigmine and memantine when treating mild and medium-severe forms of Alzheimer>s disease. The cost-minimisation analysis was a method of calculating a 2-year treatment course. The cost-effectiveness analysis was a method of comparing the pharmacological efficiency of medications. As reported, Cerebrolysin at a dose of 10 ml/day used to treat Alzheimer>s disease in mild and medium-severe forms appears to be most preferable, from the pharmacoeconomic standpoint, compared with the other drugs.
About the Authors
E. A. Poddoubniy
Pacific State Medical University
Russian Federation
Russian Federation
E. V. Eliseeva
Pacific State Medical University
Russian Federation
Russian Federation
A. P. Repiev
Research Institute of Cerebrovascular Pathology and Cerebral Accident of the Russian National Research Medical University named after N.I. Pirogov
Russian Federation
Russian Federation
Yu. V. Feoktistova
Pacific State Medical University
Russian Federation
Russian Federation
R. K. Goncharova
Pacific State Medical University
Russian Federation
Russian Federation
G. I. Geltser
Pacific State Medical University; Vladivostok State University of Economics and Service
Russian Federation
Russian Federation
References
1. Белоусов Ю.Б., Зырянов С.К., Белоусов Д.Ю. и др. Клинико-экономические аспекты терапии болезни Альцгеймера в России. Качественная клиническая практика. 2009. URL http:// www.clinvest.ru/part.php?pid=148 (дата обращения 22.01.2013).
2. Allegri R.F, Guekht A. Cerebrolysin improves symptoms and delays progression in patients with Alzheimer,s disease and vascular dementia // Drugs of Today. 2012. No. 48, Suppl. A. P. 25-41.
3. Alvarez X.A., Cacabelos R., Laredo M. et al. A 24-week, doubleblind, placebo-controlled study of three dosages of Cerebrolysin in patients with mild to moderate Alzheimer’s disease // Eur. J. Neurol. 2006. Vol. 13, №1. P. 43-54.
4. Alzheimer’s Association. 2009. Alheimer’s disease facts and figures. URL: http://www.alz.org/national/documents/report_alz-factsfigures2009.pdf (дата обращения 22.01.2013).
5. Bae C.-Y., Cho C.-Y., Cho K. et al. A double-blind, placebocontrolled, multicenter study of Cerebrolysin for Alzheimer’s disease // J. Am. Geriatr. Soc. 2000. Vol. 48, No. 12. P. 1566-1571.
6. Ferri C.P., Prince M., Brayne C. et al. Global prevalence of dementia: a Delphi consensus study // Lancet. 2005. Vol. 366. P. 2112-2117.
7. Gauthier S. Results of a 6month randomized placebo controlled study with Cerebrolysin in Alzheimers disease // Europ. J. Neurol. 1999. Vol.6, suppl. 3. P. 28.
8. Wilcock G.K., Lilienfeld S., Gaens E. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer’s disease: multicentre randomised controlled trial // BMJ. 2000. Vol. 321. P. 1445-1449.
9. Improving hospital care for persons with dementia / ed. N.M. Silverstein, K. Maslow. New York: Springer Pub. Co., 2006, 272 p.
10. Schneider L.S., Dagerman K.S., Higgins J.P.T. et al. Lack of evidence for the efficacy of memantine in mild Alzheimer disease // Arch. Neurol. 2011. doi: 10.1001/archneurol.2011.69.
11. Rosler M., Anand R., Cicin-Sain A. et al. Efficacy and safety of rivastigmine in patients with Alzheimer>s disease: international randomised controlled trial // BMJ. 1999. Vol. 318. P. 633-640.
12. Rainer M., Brunbauer M., Dunky A. Therapeutic results with Cerebrolysin in the treatment of dementia // Wien. Med. Wochenschr. 1997. Vol. 147. P. 426-431.
13. Ruether E., Alvarez X.A., Rainer M. et al. Sustained improvement of cognition and global function in patients with moderately severe Alzheimer’s disease: a doubleblind, placebo-controlled study with the neurotrophic agent Cerebrolysin // J. Neural. Transm. 2002. Vol. 62, suppl. P. 265-275.
14. Ruether E., Husmann R., Kinzler E. et al. A 28-week, doubleblind, placebo-controlled study with Cerebrolysin in patients with mild to moderate Alzheimer’s disease // Int. Clin. Psychopharmacol. 2001. Vol.16, No. 5. P. 253-263.
15. Wimo A., Winblad B., Jonsson L. An estimate of the total worldwide societal costs of dementia in 2005 // Alheimers Dement. 2007. Vol. 3. P. 81-91.
Review
For citations:
Poddoubniy E.A., Eliseeva E.V., Repiev A.P., Feoktistova Yu.V., Goncharova R.K., Geltser G.I. PHARMAECONOMIC ASPECTS OF TREATING ALZHEIMER’S DISEASE. Pacific Medical Journal. 2013;(2):80-82. (In Russ.)
Views:
244
Email this article 